Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02551081|
Recruitment Status : Recruiting
First Posted : September 16, 2015
Last Update Posted : October 30, 2018
|Condition or disease|
|Genetic Disease Multiple Malformation Congenital Malformation|
Neonatal congenital malformation is one of the most frequent cause of infant death in the western world and major cities of China. There are many different types of congenital malformations, and some of these can be caused by changes in gene mutation. Next generation sequencing (NGS) is a high-throughput parallel sequencing that can provide genetic information with high accuracy. It is a faster and cost-effective method to detect gene mutations compared to Sanger sequencing. We hope to couple genomic techniques with more traditional methods involved in genetic discovery in order to investigate a broad range of conditions for which there is strong evidence that genetic factors are involved. So In this study, we evaluated the clinical role of NGS testing for neonatal genetic disease in newborns compared to Sanger sequencing to observe whether this new technology can significantly shorten the time of examination, improve the diagnosis rate, guide the intervention treatments and promote prognosis.
These neonates who have an undiagnosed illness, and partial families, will be eligible to participate in the study. The study population will be recruited from Children's Hospital of Fudan University inpatient population, primarily the neonatal intensive care unit (NICU), with a subpopulation presenting to other hospitals in China. All affected study participants will receive a genetic screening according to their clinical symptom. All subjects will have blood drawn for DNA isolation and genomic sequencing at the time of enrollment in the study. All blood sample volumes will adhere to the Fudan procedure on maximum blood in pediatric patients. In addition, cerebrospinal fluid and tissue samples may be collected and stored in the bank of biosamples. DNA will be isolated and prepared for NGS or Sanger with Fudan protocols at the Translational Medicine Center of Children's Hospital of Fudan University. Partial familial samples will also be obtained, and nucleic acids will also be sequenced, as indicated, to assist in diagnosis of the genetic disease in the newborn. All sequencing data will be stored in the Genome Center Biorepository. In the case of positive study findings that may be diagnostic, our investigator will perform confirmatory clinical diagnostic testing and, if confirmed, a standard clinical diagnostic report will be placed in the patient's medical record. Follow up with the patient's family will be guided by the clinical care team. Both molecular diagnoses results and duration to diagnosis will be recorded as primary outcomes.
In addition, this information will help alleviate anxiety on the part of the family, and also provides a mechanism for patient crossover into the rapid NGS arm if the patient is clinically deteriorating, and at the clinical care team's request. Each time a study participant is enrolled, the clinician and parents will be asked to fill out a survey prior to NGS testing and after return of results. We will also review the patient's medical record and collect clinical variables including laboratory testing, radiology results, medications and other treatments received to further analyze the effect NGS has on clinical care. So the ultimate goal is individualized or personalized therapy. We plan to follow up with families annually up to 18 months post enrollment and record clinical outcomes related to this study.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units|
|Actual Study Start Date :||October 1, 2015|
|Estimated Primary Completion Date :||December 30, 2020|
|Estimated Study Completion Date :||December 30, 2020|
Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
- Mortality [ Time Frame: At corrected age of 18 months ]The relative frequency of deaths in each group.
- Disability Rate [ Time Frame: At corrected age of 18 months ]Disability, defined as a physical or mental handicap, especially one that prevents a person from living a full, normal life or from holding a gainful job.
- Gene Mutation [ Time Frame: In 30 days after receipt of the sample ]To detect the mutation and characterize the genetic architecture and risk variants of neonatal malformation using different genomic methods.
- Neurodevelopment(Bayley Scores) [ Time Frame: At corrected age of 18 months ]To evaluate neurodevelopmental function by Bayley Scores of Infant Development Mental Development Index (MDI), gain Incidence of MDI<70(Severe) or MDI<85(Moderate)
- Respiratory Support [ Time Frame: In 14 days after results disclosure ]To observe whether the clinical mornitoring will be changed after results disclosure
- Care Level [ Time Frame: In 14 days after results disclosure ]To observe whether the care level will be changed after results disclosure
- The total cost for hospitalization [ Time Frame: At corrected age of 18 months ]Determination of utilization of healthcare resources in hospital charges in both arms.
- Average days of hospitalization [ Time Frame: At corrected age of 18 months ]From hospital to discharge.
- Parents' understanding of study results [ Time Frame: At corrected age of 3 months ]Assessed in parent surveys via questions assessing: subjective understanding, importance of understanding.
- Parents' recall of study results [ Time Frame: At corrected age of 3 months ]Assessed in parent surveys via questions assessing: results recall
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02551081
|Contact: Wenhao Zhou, Doctorfirstname.lastname@example.org|
|Contact: Guoqiang Cheng, Doctoremail@example.com|
|Children Hospital of Fudan University||Recruiting|
|Shanghai, Shanghai, China|
|Contact: Wenhao Zhou, Doctor (+86)021-64931003 firstname.lastname@example.org|
|Study Chair:||Wenhao Zhou, Doctor||Children's Hospital of Fudan University|